Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMA5XGH)

Drug Name
Isradipine Drug Info
Synonyms
Clivoten; DynaCirc; DynaCire; Dynacrine; Esradin; Icaz; Isradipin; Isradipino; Isradipinum; Isrodipine; Lomir; Prescal; Rebriden; DynaCire CR; Dynacirc CR; Isradipino [Spanish]; Isradipinum [Latin]; PN 205 033; PN 205 034; PN 205033; PN 205034; PN205033; PN205034; DynaCirc (TN); PN 200-110; PN 205-033; PN 205-034; PN-200110; Prescal (TN); Isradipine (USP/INN); Isradipine [USAN:INN:BAN]; PN-200-110; PN-205-033; PN-205-034; Isradipine, (R)-Isomer; Isradipine, (S)-Isomer; Isradipine, (+-)-Isomer; DynaCirc, Prescal, PN-200-110, Clivoten, Esradin, Isradipine; Isopropyl methyl (+-)-4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; Isopropyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-3-pyridinecarboxylate; Methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; O5-methyl O3-propan-2-yl 4-(2,1,3-benzoxadiazol-7-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Isradipine; (+/-)-Isradipine; 2,1,3-Benzoxadiazole, 3,5-pyridinedicarboxylic acid deriv.; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-(1-methylethyl) ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester (9CI); 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 3-O-methyl 5-O-propan-2-yl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,1,3-Benzooxadiazol-4-yl)-2.6-dimethyl-1,4-dihydro-3-isopropyloxycarbonylpyridine-5-carboxylic Acid Methyl Ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methhylethyl ester; 4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester; 4-(4-Benzofurazanyl)-1,4-dihydro-2,-6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester
Therapeutic ClassAntihypertensive Agents
Cross-matching ID
PubChem CID
3784
ChEBI ID
CHEMBL1648
CAS Number
CAS 75695-93-1
TTD Drug ID
D0Z7KE
VARIDT Drug ID
DR00975
ACDINA Drug ID
D00336

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.53 0.00e+0 34/36 (94.44%) PCNA;RPA2;PRIM1;...
Proteasome 2.36 0.00e+0 44/46 (95.65%) PSMA6;PSMA1;PSMA2;...
Ribosome 2.30 0.00e+0 113/158 (71.52%) MRPS16;RSL24D1;MRPL15;...
Mismatch repair 2.13 0.00e+0 22/23 (95.65%) PCNA;RPA2;MSH2;...
Nucleotide excision repair 2.06 2.81e-3 40/47 (85.11%) PCNA;RPA2;POLE2;...
Parkinson disease 1.96 3.51e-3 176/249 (70.68%) NDUFB5;PRKACB;HSPA5;...
RNA transport 1.92 3.01e-3 128/186 (68.82%) NUP37;EIF4A3;EIF2S2;...
Homologous recombination 1.86 6.14e-3 35/41 (85.37%) RPA2;RPA3;RAD54B;...
Base excision repair 1.86 5.46e-3 29/33 (87.88%) PCNA;POLE2;POLB;...
Aminoacyl-tRNA biosynthesis 1.84 4.91e-3 15/66 (22.73%) IARS2;HARS2;GATB;...
Fanconi anemia pathway 1.81 7.65e-3 36/54 (66.67%) RPA2;CENPX;RPA3;...
Folate biosynthesis 1.76 1.29e-2 23/26 (88.46%) GGH;MOCS2;GCH1;...
Oxidative phosphorylation 1.74 1.35e-2 93/133 (69.92%) NDUFB5;PPA2;NDUFV2;...
Protein export 1.71 1.75e-2 17/23 (73.91%) HSPA5;SPCS1;SRP72;...
Type I diabetes mellitus 1.70 2.01e-2 38/43 (88.37%) CPE;ICA1;IFNG;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis 1.63 3.86e-2 20/26 (76.92%) PIGB;PIGP;PIGN;...
AGE-RAGE signaling pathway in diabetic complications -1.68 1.73e-2 97/100 (97%) MAPK3;STAT5B;NOX1;...
Pertussis -1.69 1.74e-2 64/76 (84.21%) C2;CD14;NLRP3;...
Amoebiasis -1.72 1.39e-2 99/102 (97.06%) PIK3CD;PIK3CB;LAMB2;...
Phosphatidylinositol signaling system -1.73 1.26e-2 82/97 (84.54%) IP6K2;PIK3R3;INPP5D;...
Osteoclast differentiation -1.74 1.21e-2 117/127 (92.13%) TRAF6;TGFB1;MAP2K1;...
PI3K-Akt signaling pathway -1.74 1.05e-2 317/354 (89.55%) MAP2K1;COL6A2;EGF;...
MicroRNAs in cancer -1.76 1.05e-2 146/310 (47.1%) ERBB3;EP300;SHC1;...
HIF-1 signaling pathway -1.76 1.04e-2 105/109 (96.33%) MAPK3;HKDC1;ELOB;...
Prostate cancer -1.76 1.08e-2 93/97 (95.88%) EP300;BRAF;RB1;...
FoxO signaling pathway -1.76 1.14e-2 118/131 (90.08%) RBL2;EP300;BRAF;...
Notch signaling pathway -1.77 1.19e-2 49/59 (83.05%) JAG1;EP300;NOTCH3;...
Regulation of lipolysis in adipocytes -1.77 1.26e-2 52/55 (94.55%) PTGER3;IRS1;ADCY1;...
Breast cancer -1.77 1.26e-2 119/147 (80.95%) JAG1;FZD8;FGF1;...
ECM-receptor interaction -1.78 1.33e-2 80/88 (90.91%) ITGB4;DAG1;THBS2;...
IL-17 signaling pathway -1.78 1.41e-2 84/94 (89.36%) MMP3;RELA;S100A8;...
Glioma -1.81 1.09e-2 67/75 (89.33%) PIK3R2;CDK4;AKT2;...
Complement and coagulation cascades -1.82 1.08e-2 76/85 (89.41%) PLAU;C9;CR1;...
Parathyroid hormone synthesis, secretion and action -1.82 1.06e-2 98/106 (92.45%) ARRB1;KL;RUNX2;...
Melanoma -1.83 1.15e-2 68/72 (94.44%) FGF1;BRAF;RB1;...
Kaposi sarcoma-associated herpesvirus infection -1.84 1.26e-2 172/193 (89.12%) ICAM1;KRAS;MAP2K2;...
Rheumatoid arthritis -1.86 7.53e-3 78/93 (83.87%) ICAM1;ACP5;HLA-DRA;...
C-type lectin receptor signaling pathway -1.88 6.98e-3 93/104 (89.42%) ARHGEF12;CLEC1B;MAPK3;...
Phagosome -1.89 6.28e-3 118/152 (77.63%) HLA-DPB1;DYNC1I2;MRC2;...
Legionellosis -1.89 7.18e-3 51/57 (89.47%) CD14;CR1;TLR4;...
Epithelial cell signaling in Helicobacter pylori infect... -1.90 8.37e-3 62/70 (88.57%) MAPK13;CXCR2;GIT1;...
Non-small cell lung cancer -1.91 1.00e-2 70/72 (97.22%) BRAF;STK4;RB1;...
Bladder cancer -1.92 1.26e-2 40/41 (97.56%) BRAF;RB1;ARAF;...
Lysosome -1.96 1.26e-2 115/128 (89.84%) CTSW;CLTC;ATP6V0B;...
Mineral absorption -2.17 0.00e+0 48/60 (80%) FTL;S100G;SLC31A1;...
Steroid biosynthesis -2.17 0.00e+0 19/20 (95%) SC5D;CYP27B1;TM7SF2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 3.33uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 3.33uM 24H
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H